Cancer Care Ontario | Cancer Care Ontario

209 Results

Guidelines and Advice

Best-Practice Guidance for Radiation Treatment Plan Physics Review

Status: Current

Apr 2020

Guidelines and Advice

The Use of Molecular Tools for Identifying and Guiding Treatment of Cancers of Unknown Primary

Status: Current
ID: MOTAC-7

Updated

Jan 2025

Guidelines and Advice

Recommendations for the Treatment of Patients with Clinical Stage III Non-Small Cell Lung Cancer: Endorsement of the 2019 National Institute for Health and Care Excellence Guidance and the 2018 Society for Immunotherapy of Cancer Guidance

Status: In-Review
ID: GL END 7-3
Version: 4

Apr 2020

Guidelines and Advice

An Endorsement of the 2018 Guideline on Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline

Status: In-Review
ID: 3-22
Version: N/A

Apr 2020

Guidelines and Advice

Regional Therapies for Colorectal Cancer Liver Metastases

Status: Current
ID: GL 2-30a
Version: N/A

Mar 2020

Guidelines and Advice

An Endorsement of the 2023 International Stereotactic Radiosurgery Society’s (ISRS) Guideline: A Systematic Review Informing the Management of Symptomatic Brain Radiation Necrosis After Stereotactic Radiosurgery and ISRS Recommendations

Status: Current
ID: Guideline Endorsement C50-CIDAP-3

Updated

Mar 2025

Statistical Reports

Ontario Cancer Statistics 2020

Aug 2020

Guidelines and Advice

Cancer and the Health Effects of Cannabis and Cannabinoids: An update of the systematic review by the National Academies of Sciences, Engineering, and Medicine (2017) Consensus Study Report

Status: Current
ID: ES 23-2
Version: N/A

Jun 2020

Guidelines and Advice

Locoregional Management of In-Transit Metastasis in Melanoma

Status: Current
ID: GL 8-10
Version: N/A

Feb 2020

Guidelines and Advice

Minimal Residual Disease Testing in Acute Leukemia

Status: Current
ID: MOTAC-6
Version: 2

Sep 2020

Statistical Reports

Ontario Cancer Statistics 2024

Ontario Cancer Statistics 2024 is the fifth in a series of reports that provide comprehensive information on the burden of cancer in Ontario....

New

Feb 2025

Guidelines and Advice

T-Cell Engaging Antibodies: Management of Cytokine Release Syndrome (CRS) and Immune Effector-Associated Neurotoxicity Syndrome (ICANS)

Status: Current

Updated

Mar 2025

Best-Practice Guidance for Radiation Treatment Plan Physics Review

The Use of Molecular Tools for Identifying and Guiding Treatment of Cancers of Unknown Primary

Recommendations for the Treatment of Patients with Clinical Stage III Non-Small Cell Lung Cancer: Endorsement of the 2019 National Institute for Health and Care Excellence Guidance and the 2018 Society for Immunotherapy of Cancer Guidance

An Endorsement of the 2018 Guideline on Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline

Regional Therapies for Colorectal Cancer Liver Metastases

An Endorsement of the 2023 International Stereotactic Radiosurgery Society’s (ISRS) Guideline: A Systematic Review Informing the Management of Symptomatic Brain Radiation Necrosis After Stereotactic Radiosurgery and ISRS Recommendations

Ontario Cancer Statistics 2020

Cancer and the Health Effects of Cannabis and Cannabinoids: An update of the systematic review by the National Academies of Sciences, Engineering, and Medicine (2017) Consensus Study Report

Locoregional Management of In-Transit Metastasis in Melanoma

Minimal Residual Disease Testing in Acute Leukemia

Ontario Cancer Statistics 2024

T-Cell Engaging Antibodies: Management of Cytokine Release Syndrome (CRS) and Immune Effector-Associated Neurotoxicity Syndrome (ICANS)

Pages